Clusterin expression and distribution in spermatozoa as predictor of male fertility
Molecular Reproduction and Development · 2024
DOI: 10.1002/mrd.23764 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Molecular Reproduction and Development, 2024. Verfasst von María Hernández-Herrador und 7 weiteren Autor:innen. Beteiligte Einrichtung: Reproduction Unit, Hospital Universitario Costa del Sol, Marbella, Spain. Hauptthemen laut MEDLINE: Clusterin, Fertility, Spermatozoa. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Merck-Fundación IMABIS.
Abstract (Originalsprache)
Clusterin (CLU), one of the main glycoproteins in mammalian semen and the male reproductive tract, plays a role in spermatogenesis and sperm maturation. Given the poor reliability of classic seminal studies in determining male‐fertilizing capacity and the differences in CLU abundance between normal and abnormal spermatozoa, we investigated the potential value of mRNA‐CLU levels and protein distribution in spermatozoa as markers of sperm quality and predictors of male fertility. This multicenter study included 90 patients undergoing in vitro fertilization (IVF) treatment with their partners, and a control group of 36 fertile males with normal seminograms. We assessed the relationship between IVF treatment outcomes, seminogram variables, mRNA‐CLU levels by quantitative real‐time‐PCR and CLU distribution by immunostaining in spermatozoa. Our study reveals CLU staining in the acrosome ( p = 0.002, OR 14.8, 95% CI: 2.7–79.3) and mRNA‐CLU levels ( p = 0.005, OR 10.85, 95% CI: 2.0–57.4) as independent risk factors for pregnancy failure, irrespective of traditional seminogram variables. Additionally, our results suggest that CLU, and specially its secreted isoform, constitutes a component of the protein pool that human spermatozoa can produce during its maturation process, exhibiting a variable abundance and distribution in spermatozoa from fertile men compared to those in patients with altered seminograms and infertile patients with normal seminograms. Our study is the first to identify mRNA‐CLU levels and CLU immunostaining in the spermatozoa acrosome as independent risk factors for pregnancy failure, with distribution patterns correlating with sperm maturity and seminogram alterations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reproduction Unit, Hospital Universitario Costa del Sol, Marbella, Spain.
- Research and Innovation Unit, Hospital Universitario Costa del Sol, Marbella, Spain.
- Surgical Specialties, Biochemistry, Molecular Biology and Immunology Department, Faculty of Medicine, Malaga University, Malaga, Spain.
- Instituto de Investigación Biomédica de Málaga (IBIMA)-Plataforma Bionand Research Institute, Malaga, Spain.
- Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS).
- Clinical Laboratories Area, Hospital Universitario Costa del Sol, Marbella, Spain.
Förderung
- Merck-Fundación IMABIS
Zitieren
APA
Hernández-Herrador, M., Marilina, G. A., Luisa Hortas, M., Carrillo-Lucena, S., Caracuel, Z., Castilla-Alcalá, J. A., Martín-García, D., & Redondo, M. (2024). Clusterin expression and distribution in spermatozoa as predictor of male fertility. Molecular Reproduction and Development. https://doi.org/10.1002/mrd.23764
Vancouver
Hernández-Herrador M, Marilina GA, Luisa Hortas M, Carrillo-Lucena S, Caracuel Z, Castilla-Alcalá JA, et al. Clusterin expression and distribution in spermatozoa as predictor of male fertility. Molecular Reproduction and Development. 2024. doi:10.1002/mrd.23764
BibTeX
@article{HernndezHerrador2024,
author = {Hernández-Herrador, María and Marilina, García-Aranda and Luisa Hortas, María and Carrillo-Lucena, Silvia and Caracuel, Zaira and Castilla-Alcalá, José Antonio and Martín-García, Desirée and Redondo, Maximino},
title = {Clusterin expression and distribution in spermatozoa as predictor of male fertility},
journal = {Molecular Reproduction and Development},
year = {2024},
doi = {10.1002/mrd.23764}
}
EUVIMED